Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus

Inclusion criteria

• Male and Female subjects.
• Age over 21 years old.
• Body mass index greater than or equal to 25 and less than 35 kg/m2
• Clinically stable Type 2 diabetes mellitus.
• Willing to give written informed consent and able to understand, to participate in and to comply with the study requirements.
• Willing to refrain from consumption of red wine, grape juice, and grape products beginning two weeks before and continuing throughout the entire study period.

Exclusion criteria

• Women who lactating or pregnant. All women with childbearing potential will undergo a urine pregnancy test at each visit to exclude pregnancy.
• Treatment with an investigational product within the last 30 days.
• Clinically evident major illness of other organ systems, including end-stage cancer, renal failure, or other conditions that in the opinion of the principal investigator make a clinical study inappropriate.
• Liver transaminase levels greater than 3X the upper limit of normal.
• History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
• Vitamin supplements exceeding two times the recommending daily allowance (RDA) within the last 30 days prior to screening.
• Resveratrol, green tea and isoflavone supplements within the last 30 days prior to screening.
• Subjects who practice a vegetarian or vegan diet
• Subjects taking budesonide, buspirone, eplerenone, eletriptan, felodipine, midazolam, saquinavir, sildenafil, triazolam, vardenafil, alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, irinotecan, pimozide, quinidine, sirolimus, tacrolimus, terfenadine, or warfarin.